HOPA MVZ GmbH
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At HOPA MVZ GmbH, investigators are advancing therapies for rare cardiac amyloidosis and transthyretin amyloid cardiomyopathy. The studies aim to improve survival, reduce hospitalisations, and evaluate novel antibodies and small‑molecule stabilisers.
- AL amyloidosis with cardiac involvement
- Transthyretin amyloid cardiomyopathy (ATTR‑CM)
- Evaluation of cardiovascular outcomes
- Assessment of long‑term disease stabilization
The Hamburg site leverages its multidisciplinary team to bring cutting‑edge options to patients with life‑threatening heart conditions.
Immune System Diseases
Research at the Haematologisch‑Onkologische Praxis Altona focuses on plasma‑cell dyscrasias and targeted immunotherapies. Trials test the combination of monoclonal antibodies with standard regimens to enhance response rates while closely monitoring safety and overall survival.
- AL amyloidosis treated with daratumumab plus CyBorD
- CAEL‑101 combined with plasma‑cell directed therapy
- Safety profiling of immune‑modulating agents
- Impact on overall survival in treatment‑naïve patients
By integrating patient‑centered care, the centre aims to set new standards for managing complex immune‑related disorders.
Neoplasms
The site conducts oncology studies ranging from solid tumours to lymphomas, evaluating strategies such as treatment de‑escalation and extended adjuvant therapy. Objectives include maintaining disease control, reducing toxicity, and improving recurrence‑free survival.
- Metastatic HR‑positive HER2‑negative breast cancer
- Advanced stage Hodgkin lymphoma
- Gastrointestinal stromal tumour (GIST) adjuvant therapy
- Comparison of BrECADD versus escalated BEACOPP
Through collaborative trials, HOPA MVZ seeks to deliver more effective and tolerable cancer treatments for patients across Hamburg and beyond.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Alexion Pharmaceuticals Inc.3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in HOPA MVZ GmbH
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Phase III Study of Adjuvant Imatinib for Recurrence-Free Survival in High-Risk Operable Gastrointestinal Stromal Tumor Patients | Region Skane | Phase III | Not Recruiting | Nov 2014 | — |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alxn2220 | 2 | Unknown | 2024-04-30 | 2024-04-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.